spacer
home > white papers > The Role of the CRO in Effective Risk-Based Monitoring - Medpace
WHITE PAPERS
logo_Medpace.JPG

Medpace

phone +1.513.579.9911
email info@medpace.com
web http://www.medpace.com
email Medpace 5375 Medpace Way, Cincinnati, Ohio, 45227

The Role of the CRO in Effective Risk-Based Monitoring

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.

Realizing the potential of RBM requires early planning, analytical expertise, sophisticated tools and process adaptability. Deep cross-functional expertise early in the trial process enhances the ability to assess overall risk, define critical data and processes, develop an integrated plan for addressing risk, and execute a monitoring plan that meets the trial’s unique requirements.
The Role of the CRO in Effective Risk-Based Monitoring
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics

Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces bioZen – a new series of LC solutions for bioseparations in pharmaceutical, biopharmaceutical and academic research. The series encompasses both proven and entirely new media spanning two particle platforms – core-shell and thermally modified fully porous – along with new biocompatible titanium hardware. The initial bioZen product line features seven chemistries for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal antibodies, antibody-drug conjugates and biosimilars. The offering includes specific LC chemistries for the analysis of aggregates and total mAb, intact mass and fragments, peptide mapping and quantitation and glycan mapping.
More info >>


White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>


Industry Events

Pharmaceutical Packaging and Device Labelling Europe

11-12 September 2018, Munich, Germany

Relaunching the event after a three year hiatus, Pharma Packaging and Labelling Europe is back to deliver key, actionable insight on the very latest regulatory requirements, technological innovations, strategic developments, and how to implement them into your packaging and labelling chain with both maximum efficiency and minimal cost. The conference is packed with thought provoking innovative discussions.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement